AAN 2021 | Research needs to address neurologic complications of immune checkpoint inhibitor use

Karin Woodman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the management of neuroimmunological adverse events associated with the use of immune checkpoint inhibitors (ICIs) for cancer treatment. Neurologic complications can be severe and even fatal in some patients, especially when used in combination. Dr Woodman highlights the importance of developing biomarkers capable of reliably predicting patients most at risk of developing complications, so they can be monitored more closely. Additionally, Dr Woodman talks on the need for highly specific treatments that target particular aspects on the immune system to best treat these patients. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.